Alnylam, Sanofi RNAi Candidate Patisiran Aces Phase III Trial

Alnylam and Sanofi today reported successful Phase III results for their rare disease RNAi candidate patisiran, saying the treatment showed “highly significant” improvement in hereditary ATTR (hATTR) amyloidosis patients with polyneuropathy.In the Phase III APOLLO trial, patisiran met its primary efficacy endpoint of change from baseline in the modified neuropathy impairment score (mNIS+7) at 18 months, and met all six of the study’s secondary endpoints, the companies said. APO